Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exelixis

Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug

Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Investors Business Daily

Dow Jones Futures: S&P 500 Erases 2025 Loss On Nvidia-Saudi Deal; Palantir, Carvana Break Out

The S&P 500 is positive in 2025 as Nvidia flashed a buy signal on Saudi AI news. Palantir and Carvana led breakouts.

Investors Business Daily

Exelixis Catapults To Record High After Obliterating First-Quarter Expectations

Exelixis stock catapulted Wednesday after the biotech trounced first-quarter expectations and raised its 2025 sales outlook by $100 million.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points

Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,

Investors Business Daily

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally.

Investors Business Daily

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

Analysts are bullish on Carpenter Technology and Exelixis

Investors Business Daily

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investors Business Daily

Exelixis Shows Rising Price Performance With Jump To 93 RS Rating

Exelixis sees its Relative Strength Rating move into the elite 90-plus level.

Investors Business Daily

Dow Jones Futures Fall With Inflation Data On Tap; Trump Stock Dives After Presidential Debate

Futures fell while Donald Trump stock DJT dived after the Trump-Harris debate Tuesday night. The CPI inflation report is due before the open.

Investors Business Daily

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

Investors Business Daily

Dow Jones Futures Fuel New Market Rally On Bank Of Japan; Nvidia Partner Super Micro Dives

Futures added to a new market rally attempt thanks to Bank of Japan comments. Nvidia partner Super Micro was a big earnings loser.

Investors Business Daily

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.

StockNews.com

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

Investors Business Daily

Exelixis Stock Sees Rising Relative Strength Rating

Exelixis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 87.

Investors Business Daily

Exelixis Stock Flashes Improved Relative Price Strength With Upgrade

Exelixis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Exelixis shows improving technical performance. Will it continue?

Investors Business Daily

Exelixis Stock Shows Market Leadership, Earns 81 RS Rating

Exelixis sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Exelixis Stock Generating Improved Relative Strength Rating

A Relative Strength Rating upgrade for Exelixis shows improving technical performance. Will it continue?

Investors Business Daily

Dow Jones Futures: Inflation Report Looms For Market Rally; Twitter Rallies As Elon Musk Sells More Tesla Stock

July's CPI inflation report is due for the market rally. Elon Musk sold $6.9 billion of Tesla stock as Twitter deal odds rise. TSLA and TWTR rose.

Investors Business Daily

Exelixis Stock Undercuts Key Line As Guidance Drags On Quarterly Beat

Exelixis easily beat second-quarter expectations, but kept its 2022 outlook and EXEL stock crumbled Wednesday.

Benzinga

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Investors Business Daily

Exelixis Stock Flashing Renewed Technical Strength, Hitting RS Of 90

Exelixis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.